A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
GlaxoSmithKline
GlaxoSmithKline
Centre Oscar Lambret
National Cancer Institute (NCI)
Georgetown University
Compass Therapeutics
Peking University Third Hospital
Washington University School of Medicine
WestVac Biopharma Co., Ltd.
On Target Laboratories, LLC
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Fudan University
Dana-Farber Cancer Institute
The University of Hong Kong
Fred Hutchinson Cancer Center
GlaxoSmithKline
Helios University Hospital Wuppertal
University of California, Irvine
Queen Mary Hospital, Hong Kong
Institut Paoli-Calmettes
Hospital Universitari de Bellvitge
M.D. Anderson Cancer Center
PapiVax Biotech, Inc.
Ankara University
Qilu Pharmaceutical Co., Ltd.
Washington University School of Medicine
The First Affiliated Hospital of Soochow University
University of Aarhus
University of Cincinnati
Convalife (Shanghai) Co., Ltd.
Erasmus Medical Center
New Mexico Cancer Research Alliance
Cancer Research UK
Rutgers, The State University of New Jersey
Kaiser Permanente
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Ellele Health
UNC Lineberger Comprehensive Cancer Center
University of Chicago
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Zhejiang University
Mayo Clinic
Mayo Clinic
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
University Hospital, Strasbourg, France
University of Southern California
Fundacion Clinic per a la Recerca Biomédica
University of Maryland, Baltimore
International Agency for Research on Cancer
AbbVie
Jiangsu Cancer Institute & Hospital